Collaborate with the patient to determine therapy and follow-up plan. *ASCVD Risk Predictor Plus is available at: http://tools.acc.org/ASCVD-Risk- Estimator-Plus/#!/calculate/estimate/ and http://static.heart.org/riskcalc/app/ index.html#!/baseline-risk. Accessed September 1, 2018. Mayo Clinic Statin Decision Aid information is available at: https:// statindecisionaid.mayoclinic.org. CardioSmart health information is available at: https://www.cardiosmart. org/About. AHA Life's Simple 7 information is available at: https://www.heart.org/en/ healthy-living/healthy-lifestyle/my-life-check lifes-simple-7. NLA Patient Tear Sheets information is available at: https://www.lipid.org/ practicetools/tools/tearsheets. PCNA Heart Healthy Toolbox information is available at: http://pcna.net/ clinical-tools/tools-for-healthcare-providers/heart-healthy-toolbox. AHA indicates American Heart Association; ASCVD, atherosclerotic cardiovascular disease; CAC, coronary artery calcium; CKD, chronic kidney disease; HIV, human immunodeficiency virus; LDL-C, low-density lipoprotein cholesterol; PCNA, Preventive Cardiology Nurses Association and NLA, National Lipid Association. CLINICAL STATEMENTS AND GUIDELINES individuals whose ASCVD risk may indicate risk of genetic hypercholesterolemia and hence who may benefit from a moderate- to high-intensity (Table 6). 5. In those with intermediate ASCVD risk, defined as an ASCVD risk of 7.5% to 20%, knowledge of risk-enhancing factors is useful in understand- ing patient characteristics that increase ASCVD risk both short and long-term (Table 6). As in the 2013 ACC/AHA guideline, an ASCVD score does not assign a statin; it begins the decision process, which includes consideration of risk-enhancing factors. For example, in an RCT,S4.4.2-9 a family history of premature ASCVD identified women 60 years of age with elevated high-sensitivity C-reactive protein but without ASCVD who ben- efitted from high-intensity statin therapy. Those with primary elevations of LDL-C 160 mg/dL (4.1 mmol/L) have elevated lifetime ASCVD risk and benefit from statin therapy.S4.4.2-21,S4.4.2-22,S4.4.2-25, Increased ASCVD riskS4.4.2-2 is seen with metabolic syndrome;S4.4.2-20 inflammatory diseases, including psoriasisS4.4.2-31 and RA; and HIV when treated with protease inhibitors.S4.4.2-32 In women, a history of pregnancy complicated by preeclampsia or premature menopause (age <40 years) also enhances ASCVD risk (see Section 4.4.5.3.). 